The government’s decision to exempt 17 drugs used in Cancer treatment from duties is a major step toward improving affordability and access to life-saving therapies. This move is expected to significantly reduce treatment costs, easing the financial burden on patients and families.
Experts believe it will enhance accessibility to advanced medications, encourage timely treatment, and improve overall patient outcomes. It also reflects a strong policy focus on healthcare support and cancer care. Ensuring efficient distribution and availability of these drugs will be crucial to maximize the benefits of this initiative across the country.
